US Outcomes-Based Contracts In Oncology? CAR-T Could Be Case Study
Executive Summary
Groundbreaking but potentially very expensive new CAR-T treatments for cancer could be suited to outcomes-based contracts, Harvard Pilgrim's Sherman suggests.
You may also be interested in...
Rising Tide Lifts All CAR-T Ships After Gilead/Kite Deal, Kymriah Approval
Excitement around cell therapy has been building in recent years, but companies expect interest to accelerate after Gilead agreed to buy Kite for $11.9bn and Novartis won the first ever CAR-T approval.
Bayer's Weinand On Broadening Value-Based Pricing Views
Bayer's pharma head Dieter Weinand talks about his biggest issues with current value-based pricing assessments for new drugs and how companion diagnostics will pave the way to easier pricing of oncology therapies.
Too Sick For CAR-T? Kite Reports Cerebral Edema Death
Kite Pharma investors were spooked on May 8 when the company revealed that an extremely ill patient died from cerebral edema related to its lead CAR-T candidate – the same severe side effect that derailed Juno's competing cell therapy.